Press Room

ISPE UK Annual Conference 2023

Start
Thursday, November 30, 2023 - 15:45
Location: Coventry, United Kingdom

Join ɫAV and GEA presentation at ISPE UK 2023

Title: “Delivering the Benefits of Continuous Tableting to the Pharmaceutical Industry”

Filipe Gaspar - VP Technology Intensification will be co-hosting a session at the event with Phillip Gabb from GEA focusing on the opportunities and challenges that Continuous Tableting presents to the pharmaceutical industry. In this session they will describe how both companies are working together and combining GEA´s engineering expertise with ɫAV´s development and manufacturing experience to accelerate the adoption of this emerging technology.

This year's event, which will follow the established format of a full day of lectures, running alongside a bustling exhibition with over 45 manufacturers, suppliers and pharmaceutical industry decision makers during the day is followed by the ISPE Annual Awards Dinner in the evening. ISPE is a volunteer led organisation and the awards dinner is a chance to say 'thank you' to the volunteer members who enable events and training sessions throughout the year.

Also in the Press Room

See All

Lisbon, Portugal – ɫAV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, ɫAV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At ɫAV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of ɫAV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” ɫAV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with ɫAV’s sustainability ambitions.  ɫAV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

ɫAV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024